Aidoc Raises $150M for Clinical AI Foundation Model

Aidoc Medical Ltd. announced a new financing event totaling approximately $150 million, reported by SiliconANGLE and reflected in the company announcement. SiliconANGLE reports that Goldman Sachs led the Series C round, while Aidoc's own announcement describes General Catalyst and Square Peg as lead investors; both sources list NVentures, NVIDIA's venture arm, among participants. SiliconANGLE reports Aidoc's total outside funding now exceeds $500 million.

According to Aidoc's announcement, the company's platform aiOS is powered by a custom healthcare foundation model called the Clinical AI Reasoning Engine, presented as CARE. Aidoc stated that the U.S. Food and Drug Administration cleared CARE in January for diagnostic tasks across 11 disease indicators. Per the company announcement reported by SiliconANGLE, CARE achieves specificity up to 99.7% and a mean specificity of 98% across the approved indicators. SiliconANGLE reports that aiOS has been installed in nearly 2,000 hospitals worldwide. The company materials describe aiOS capabilities including image analysis, integration of electronic health results and vitals, incidental finding prioritization, mobile alerts, spreadsheet-style patient tracking, and automated clinical trial matching.

Foundation models that combine imaging and structured clinical data are an active direction in medical AI research. Industry observers note multi-modal approaches can improve diagnostic context when models ingest images plus lab values and vitals. For practitioners, this raises operational questions around data integration, model calibration across site populations, and workflow embedding for rapid triage and alerting.

Large, later-stage financings in healthcare AI, coupled with regulatory clearances, increase vendor scrutiny from hospital procurement and compliance teams. Reported specificity claims such as 99.7% are material for clinical adoption, but independent validation and peer-reviewed performance across diverse patient cohorts remain central to clinical trust and reimbursement discussions.

Monitor independent evaluations of CARE performance, publication of validation studies, and wording in FDA documentation for scope and intended use. Also watch contracting and deployment patterns across health systems that participated in the round, as well as any provider-reported integration challenges between aiOS and electronic health record systems.